TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity
- Author(s)
- Shallis, RM; Daver, NG; Altman, JK; Hasserjian, RP; Kantarjian, HM; Platzbecker, U; Santini, V; Wei, AH; Sallman, DA; Zeidan, AM;
- Details
- Publication Year 2023-01-15,Volume 129,Issue #2,Page 175-180
- Journal Title
- Cancer
- Publication Type
- Review
- Abstract
- TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.
- Publisher
- Wiley
- Keywords
- Humans; *Myelodysplastic Syndromes/drug therapy; *Leukemia, Myeloid, Acute/genetics/drug therapy; Leukocytes; Tumor Suppressor Protein p53/genetics; Tp53; acute myeloid leukemia (AML); cutoff; excess blasts; myelodysplastic syndrome (MDS); p53
- Department(s)
- Clinical Haematology
- PubMed ID
- 36397669
- Publisher's Version
- https://doi.org/10.1002/cncr.34535
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-06-13 07:55:28
Last Modified: 2023-06-13 07:56:08